Proteinuria and VEGF-targeted therapies:  an underestimated toxicity?
Oncologists and nephrologists usually manage proteinuria related to anti-vascular endothelial growth factor (anti-VEGF) treatment only when it is in the nephrotic range or associated with renal insufficiency. This report is based on our personal experience with 78 patients developing renal problems with anti-VEGF therapy. We found that proteinuria induced by anti-VEGF therapy, even if weak and without associated renal insufficiency, may reflect a serious histological renal disease.
Department of Nephrology, Pitie Salpetriere Hospital, Pierre et Marie Curie University, Paris - France.
Hassane
H
Izzedine
Jean Charles
JC
Soria
Bernard
B
Escudier
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D057915:Drug Substitution; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011507:Proteinuria / Q000139:chemically induced* / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D012307:Risk Factors; D012720:Severity of Illness Index; D015398:Signal Transduction / Q000187:drug effects*; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A